KALA BIO (NASDAQ:KALA) Earns Outperform Rating from Oppenheimer

Oppenheimer reissued their outperform rating on shares of KALA BIO (NASDAQ:KALA) in a report published on Monday, Benzinga reports. The firm currently has a $15.00 price target on the stock.

Separately, HC Wainwright dropped their price objective on KALA BIO from $21.00 to $18.00 and set a buy rating on the stock in a report on Friday, May 17th.

KALA BIO Stock Down 3.7 %

KALA BIO stock opened at $5.99 on Monday. The company has a quick ratio of 4.22, a current ratio of 4.22 and a debt-to-equity ratio of 4.92. The company has a market capitalization of $16.87 million, a P/E ratio of -0.40 and a beta of -2.03. The firm has a 50 day moving average price of $6.39 and a 200-day moving average price of $6.86. KALA BIO has a twelve month low of $4.21 and a twelve month high of $14.50.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Tuesday, August 6th. The company reported ($3.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.40) by $1.24. As a group, equities analysts predict that KALA BIO will post -14.49 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Mark T. Iwicki sold 15,168 shares of the business’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $4.75, for a total transaction of $72,048.00. Following the completion of the transaction, the chief executive officer now directly owns 263,755 shares in the company, valued at approximately $1,252,836.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other KALA BIO news, CEO Mark T. Iwicki sold 7,392 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $6.09, for a total value of $45,017.28. Following the completion of the transaction, the chief executive officer now owns 278,923 shares of the company’s stock, valued at approximately $1,698,641.07. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Mark T. Iwicki sold 15,168 shares of KALA BIO stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $4.75, for a total transaction of $72,048.00. Following the sale, the chief executive officer now directly owns 263,755 shares of the company’s stock, valued at $1,252,836.25. The disclosure for this sale can be found here. Insiders have sold 35,255 shares of company stock worth $182,564 in the last three months. 13.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On KALA BIO

Several institutional investors have recently modified their holdings of KALA. Knights of Columbus Asset Advisors LLC boosted its stake in KALA BIO by 100.0% in the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 4,834 shares of the company’s stock worth $34,000 after buying an additional 2,417 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of KALA BIO in the 4th quarter worth approximately $30,000. Finally, SR One Capital Management LP purchased a new stake in shares of KALA BIO in the 2nd quarter valued at $3,146,000. 24.61% of the stock is currently owned by institutional investors.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.